Adult-Onset Vanishing White Matter Disease Due to a Novel EIF2B3 Mutation

Robert La Piana, MD; Adeline Vanderver, MD; Marjo van der Knaap, MD, PhD; Louise Roux, MD; Donatella Tampieri, MD; Bernard Brais, MD, PhD; Geneviève Bernard, MD, MSc, FRCP(C)

Objective: To report a novel mutation in the gene EIF2B3 responsible for a late-onset form of vanishing white matter disease.

Design: Case report.

Setting: University teaching hospital.

Patient: A 29-year-old pregnant woman with a history of premature ovarian failure and hemiplegic migraines presented with a 10-week history of progressive confusion and headaches. Magnetic resonance imaging of the brain revealed a diffuse leukoencephalopathy.

Results: Sequencing of the exons and intron boundaries of EIF2B3 uncovered 2 missense mutations: c.260C>T (p.Ala87Val) and c.272G>A (p.Arg91His). To our knowledge, the latter missense mutation has never been previously reported.

Conclusion: This is the second report of adult-onset vanishing white matter disease due to mutations in EIF2B3 and the first report of the c.272G>A (p.Arg91His) missense mutation.


Vanishing white matter disease (VWM; OMIM 603896), also called childhood ataxia with central hypomyelination, is one of the most common leukodystrophies. It is an autosomal recessive leukoencephalopathy with typical onset in the pediatric age group. It is estimated that adulthood-onset VWM represents 15% of cases. The classic phenotype is characterized by an onset between the first and fifth years of life, with prominent cerebellar ataxia and spasticity. The disease is typically slowly progressive with episodes of neurological deterioration classically triggered by stressful events (eg, fever, infections, mild head trauma, or even fright). The evolution of the disease is highly variable, from patients dying within 1 to 5 years of disease onset to a much slower progression.

Patients with the adult-onset form of the disorder typically have a milder and more insidious clinical course characterized by behavioral changes, dementia, and seizures. A few cases have presented with complicated migraines. The typical stress-related acute neurological deteriorations are less frequent in adult-onset cases. Ovarian failure is frequently reported in women with VWM and can precede the neurological symptoms, leading to the name ovarioleukodystrophy. Interestingly, gene mutations in EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5 are extremely rare among subjects with premature ovarian failure.

Neuroradiological findings of VWM are specific. Brain magnetic resonance imaging typically shows diffuse and symmetric white matter hyperintensities on T2-weighted imaging, with possible sparing of the U fibers, the outer rim of the corpus callosum, the anterior commissure, and the internal capsule. The cerebral white matter typically progresses to cystic degeneration and rarefaction, best visualized in fluid-attenuated inversion recovery or proton density sequences. The cerebellar and brainstem white matter can be affected as well, but no cystic degeneration has been reported. Magnetic resonance spectroscopy may show a global reduction of all metabolites.

Mutations in any of the 5 genes encoding the eukaryotic translation initiation factor 2B (EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5) are responsible for the disease. Patients usually have a compound heterozygous status. Mutations in EIF2B3 are the most common, accounting for approximately 60% to 70% of all cases of VWM. The Arg113His mutation is one of the most common.
mutation is the most frequent and is usually associated with the adult-onset form. We report an atypical case of adult-onset VWM carrying a novel mutation in \textit{EIF2B3} (GenBank NM_020365.2).

**REPORT OF A CASE**

This patient was first seen by our neurogenetics team at age 29 years for an acute episode of migraine, fever, and encephalopathy. She had been pregnant for 10 weeks at the time and had constant headache with intermittent left hemibody paresthesias, aphasia, nausea, and vomiting since the beginning of her pregnancy. The patient was the second daughter of nonconsanguineous French Canadian parents. The family history was unremarkable. Her medical history was significant for hemiplegic migraines since age 20 years as well as secondary amenorrhea and premature ovarian failure. Magnetic resonance imaging of the brain performed at age 21 years revealed a diffuse leukoencephalopathy; magnetic resonance spectroscopy showed a reduction of all metabolites. The investigations performed at the time did not uncover the cause of her leukoencephalopathy. On arrival to the emergency department, the degree of her encephalopathy limited the neurological examination. Laboratory investigations failed to show any abnormality except mild leukocytosis. Electroencephalography revealed a slow background without epileptic abnormality. During the course of her admission, the patient’s encephalopathy subsided and, as she became more collaborative, mild cerebellar signs were noted. In the following month, she gradually improved but did not recover completely; she remained with impaired cognitive status and behavioral disturbances. Magnetic resonance imaging of the brain confirmed the known diffuse and symmetric cerebral and cerebellar white matter abnormalities, with hyperintense signal on T2-weighted images (Figure 1) and hypointense signal on T1-weighted images (Figure 2). Small cystic areas were seen bilaterally at the frontal horns on a fluid-attenuated inversion recovery sequence (Figure 1B). Otherwise, there was no evidence of white matter rarefaction or cystic degeneration.

On the basis of the clinical features, the history of ovarian failure, and the magnetic resonance imaging pattern, adult-onset VWM was suspected. Genetic testing for the 5 EIF2B genes was performed (PreventionGenetics) and uncovered 2 mutations in EIF2B3: c.260C>T (p.Ala87Val) and c.272G>A (p.Arg91His) (Figure 3). To our knowledge, the second mutation in exon 3 has never been reported but is thought to be pathogenic because it leads to an amino acid substitution (p.Arg91His).
ure26 was observed in our case; despite the previous diagnosis of early menopause, the patient became pregnant unexpectedly without any hormone replacement therapy or in vitro fertilization. This event can be explained only by considering residual ovarian functionality.

The trigger event for the rapid deterioration in our patient is not completely established, but the role of the pregnancy should be taken into account. Another case of rapid neurological deterioration was described in a patient who had undergone in vitro fertilization and had been pregnant for 4 weeks.8 The important physical and psychological changes occurring in the first trimester as well as in the last weeks of gestation, especially the labor, may be considered potentially stressful events.27 Both the case reported by Peter et al and our case had a history of leukoencephalopathy and premature ovarian failure when the acute neurological deterioration occurred during pregnancy, suggesting the diagnosis of VWM.

In conclusion, our patient is the second adult-onset case of VWM with mutations in EIF2B3 reported in the literature and the first, to our knowledge, with the c.272G>A (p.Arg91His) missense mutation in exon 3. Hemiplegic migraines are an unusual but possible presenting manifestation of this disorder, and it is important to consider the diagnosis of adult-onset VWM disease in patients with leukoencephalopathy and premature ovarian failure with or without neurological deterioration.

Accepted for Publication: September 7, 2011.
Correspondence: Geneviève Bernard, MD, MSc, FRCP, Montreal Children’s Hospital, 2300 Tupper, Room A-506, Montreal, QC H3H1P3, Canada (genevieve.bernard@muhc.mcgill.ca).

Author Contributions: Study concept and design: Brais and Bernard. Acquisition of data: Vanderver, Roux, and Brais. Analysis and interpretation of data: La Piana, Vanderver, van der Knaap, and Tampieri. Drafting of the manuscript: La Piana. Critical revision of the manuscript for important intellectual content: Vanderver, van der Knaap, Roux, Tampieri, Brais, and Bernard. Administrative, technical, and material support: Vanderver. Study supervision: Brais and Bernard.

Financial Disclosure: None reported.

Funding/Support: Dr La Piana has received a fellowship grant from the Montreal Neurological Institute. Dr Vanderver has received support from the American Academy of Neurology Foundation. Dr van der Knaap is supported by TOP grant 9120.6002 from the Dutch Organisation for Scientific Research (ZonMw) and grant 2008029 WO from the Dr W. M. Phelps Foundation. Drs Brais and Bernard have received research funds from the Fondation des Leu-
ciodystrophies and the European Leukodystrophy Foundation. Dr Bernard has received fellowship grants from the Fonds de Recherche en Santé du Québec.

Additional Contributions: We thank the patient for her participation in this study and Luc Marchand, MD, FRCP, for referring the patient. PreventionGenetics performed the genetic testing and provided the color chromatogram of the 2 mutations.

REFERENCES


